System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40133696 DOI: 10.1038/s41598-025-94725-4

Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.

Sci Rep 15(1):10343

Authors: Alba Sánchez, Graciano García-Pardo, Anna Martí, Frederic Gómez-Bertomeu, Silvia Chafino, Marta Massanella, Marina Flores-Piñas, Lídia Cedó, Francesc Vidal, Joaquim Peraire, Anna Rull

Affiliations

  • Infection and Immunity (INIM), Institut Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Universitat Rovira i Virgili (URV), Tarragona, Spain.
  • IrsiCaixa, Hospital Universitari Germans Trias i Pujol, 08916, Badalona, Spain.
  • Grup de Recerca en Diabetis i Malalties Metabòliques Associades (DIAMET), Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari Joan XXIII, Tarragona, Spain.
  • CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Infection and Immunity (INIM), Institut Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Universitat Rovira i Virgili (URV), Tarragona, Spain.
  • Infection and Immunity (INIM), Institut Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Universitat Rovira i Virgili (URV), Tarragona, Spain.

Abstract

Hypertension is one of the most common risk factors for COVID-19 clinical progression. The identification of plasma biomarkers for anticipating worse clinical outcomes and to better understand the shared mechanisms between hypertension and COVID-19 are needed. A hypothesis-generating study was designed to compare plasma proteomics and metabolomics between 22 hypertensives (HT) and 41 non-hypertensives (nHT) patients with the most unfavorable COVID-19 progression. A total of 43 molecules were significantly differed between HT (n = 22) and nHT (n = 41). Random Forest (RF) analysis identified myo-inositol, gelsolin and phosphatidylcholine (PC) 32:1 as the top molecules for distinguishing between HT and nHT. Plasma myo-inositol and gelsolin were higher (P = 0.03 and P = 0.02, respectively) and plasma PC 32:1 was lower (P = 0.03) in HT compared to nHT. Biological processes like stress response and blood coagulation, along with KEGG pathways including ascorbate and aldarate metabolism (P = 0.021) and linoleic acid metabolism (P = 0.028), were altered in hypertensive patients with the most unfavorable COVID-19 progression. There is a clear link between hypertension and severe COVID-19. Key biological pathways to consider for improving the prognosis and quality of life of hypertensive patients who become infected with SARS-CoV-2 include oxidative stress, ascorbate and aldarate metabolism, lipid metabolism, immune system and inflammation.

MeSH

Hypertension, Stress, Physiological, Inositol, Biomarkers, Covid-19, Natural Science Disciplines, Gelsolin, Plasma

Cited by